` LONN (Lonza Group AG) vs Swiss Market Index Comparison - Alpha Spread

LONN
vs
Swiss Market Index

Over the past 12 months, LONN has outperformed Swiss Market Index, delivering a return of 17% compared to the Swiss Market Index's 2% growth.

Stocks Performance
LONN vs Swiss Market Index

Loading
LONN
Swiss Market Index
Add Stock
www.alphaspread.com

Performance Gap
LONN vs Swiss Market Index

Loading
LONN
Swiss Market Index
Difference
www.alphaspread.com

Performance By Year
LONN vs Swiss Market Index

Loading
LONN
Swiss Market Index
Add Stock

Competitors Performance
Lonza Group AG vs Peers

Swiss Market Index
LONN
0KHE
TMO
DHR
207940
Add Stock

Lonza Group AG
Glance View

Market Cap
39.8B CHF
Industry
Life Sciences Tools & Services

Amidst the serene valleys and bustling innovation hubs of Switzerland, Lonza Group AG has carved an indelible niche in the dynamic world of life sciences. Established in 1897, this stalwart of the biotech and pharmaceutical industry seamlessly blends traditional Swiss precision with cutting-edge scientific inquiry. Originally a chemical company, Lonza has reinvented itself over the years, today standing as a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and nutrition sectors. From delivering small molecules and complex biologics to pioneering innovations in cell and gene therapy, Lonza's versatile and expansive portfolio underscores its core strength: fostering the seamless transition from early-stage research to full-scale manufacturing. This unique capability leverages a vast network of state-of-the-art facilities and expert talent, enabling Lonza to nurture groundbreaking therapies from concept through to market readiness. The secret to Lonza's business model lies in its adept mix of contract development and manufacturing (CDMO) services, enabling it to partner with a diverse clientele ranging from nimble biotechs to giant pharmaceutical firms. This breadth of collaboration adds a layer of stability and scale to its operations, generating revenue through long-term manufacturing agreements and comprehensive development programs. Lonza thrives on its ability to tailor its offerings, providing customized support at various stages of a drug’s lifecycle — from early discovery to commercial supply. Furthermore, their expansion into high-growth areas such as personalized medicine and biotechnology bolsters their competitive edge while aligning with market demand trends. This strategic alignment, coupled with a relentless pursuit of operational excellence and innovation, propels Lonza's enduring legacy as both a powerhouse and a partner in forging the future of medicine.

LONN Intrinsic Value
501.22 CHF
Overvaluation 12%
Intrinsic Value
Price
Back to Top